Clinical trial · Interventional
EUS Guided Celiac Neurolysis
Prospective Randomized Trial of EUS Guided Celiac Ganglia Neurolysis (CGN) Versus EUS Guided Celiac Plexus Neurolysis (CPN) for Pancreatic Cancer Pain
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
* Hypothesis: \- Direct CGN enhances neurolytic drug delivery into celiac ganglia and increases the efficacy of neurolysis and subsequent pain control and survival in patients with pancreatic carcinoma. * Rationale: * Standard CPN leads to inaccurate delivery of the injectate with rapid dispersal thereby only briefly remaining in contact with neural structures and limiting the degree of neurolysis. Poor targeting and delivery of a neurolytic agent may result in diminished neurolysis and decrease efficacy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer Pain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EUS | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- EUS 1
- interventionNames
- Procedure: EUS
- type
- ACTIVE_COMPARATOR
- label
- EUS 2
- interventionNames
- Procedure: EUS
Primary outcomes (1)
- measure
- Pain assessed using a numerical rating scale (NRS) from 0 to 10.
- timeFrame
- Baseline to 6 months
- description
- pain response will be measured
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * 1\. Unresectable pancreatic carcinoma (T4 or M1) or advanced T3 disease * 2\. Cytologic or histologic confirmation of pancreatic carcinoma * 3\. Abdominal pain (≥ 3 on NRS scale), ≥ 2 days/week, lasting ≥ 1 hour/ day, stable intensity for ≥ 7 days * 4\. EUS clinically indicated (for non-study purposes) Exclusion Criteria: * 1\. Uncorrectable coagulopathy: (INR) \> 1.5 and/or platelets \< 50,000 * 2\. Abdominal surgery within 1 month * 3\. Prior celiac plexus or ganglia neurolysis. * 4\. Initiation or modification in chemotherapy or radiotherapy within prior 7 days. * 5\. Direct tumor infiltration of the celiac trunk and/or celiac ganglia.
References
Publications (1)
- DERIVEDLevy MJ, Gleeson FC, Topazian MD, Fujii-Lau LL, Enders FT, Larson JJ, Mara K, Abu Dayyeh BK, Alberts SR, Hallemeier CL, Iyer PG, Kendrick ML, Mauck WD, Pearson RK, Petersen BT, Rajan E, Takahashi N, Vege SS, Wang KK, Chari ST. Combined Celiac Ganglia and Plexus Neurolysis Shortens Survival, Without Benefit, vs Plexus Neurolysis Alone. Clin Gastroenterol Hepatol. 2019 Mar;17(4):728-738.e9. doi: 10.1016/j.cgh.2018.08.040. Epub 2018 Sep 12. PMID 30217513